Ixabepilone: Difference between revisions
Content deleted Content added
Activating IUPHAR link. Report errors and suggestions to User_talk:BogBot |
|||
| Line 63: | Line 63: | ||
==Pharmacology== |
==Pharmacology== |
||
It acts to stabilize [[microtubule]]s.<ref name="pmid18321240">{{cite journal |author=Denduluri N, Swain SM |title=Ixabepilone for the treatment of solid tumors: a review of clinical data |journal=Expert Opin Investig Drugs |volume=17 |issue=3 |pages=423–35 |date=March 2008 |pmid=18321240 |doi=10.1517/13543784.17.3.423 |url=http://www.expertopin.com/doi/abs/10.1517/13543784.17.3.423}}</ref><ref name="pmid18945860">{{cite journal |author=Goodin S |title=Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer |journal=Am J Health Syst Pharm |volume=65 |issue=21 |pages=2017–26 |date=November 2008 |pmid=18945860 |doi=10.2146/ajhp070628 |url=http://www.ajhp.org/cgi/pmidlookup?view=long&pmid=18945860}}</ref> |
It acts to stabilize [[microtubule]]s.<ref>{{cite journal|last1=Lopus|first1=M|last2=Smiyun|first2=G|last3=Miller|first3=H|last4=Oroudjev|first4=E|last5=Wilson|first5=L|last6=Jordan|first6=MA|title=Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.|journal=Cancer Chemother Pharmacol|date=2015|volume=76|pages=1013-24|doi=10.1007/s00280-015-2863-z|pmid=26416565|url=http://www.ncbi.nlm.nih.gov/pubmed/26416565}}</ref><ref name="pmid18321240">{{cite journal |author=Denduluri N, Swain SM |title=Ixabepilone for the treatment of solid tumors: a review of clinical data |journal=Expert Opin Investig Drugs |volume=17 |issue=3 |pages=423–35 |date=March 2008 |pmid=18321240 |doi=10.1517/13543784.17.3.423 |url=http://www.expertopin.com/doi/abs/10.1517/13543784.17.3.423}}</ref><ref name="pmid18945860">{{cite journal |author=Goodin S |title=Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer |journal=Am J Health Syst Pharm |volume=65 |issue=21 |pages=2017–26 |date=November 2008 |pmid=18945860 |doi=10.2146/ajhp070628 |url=http://www.ajhp.org/cgi/pmidlookup?view=long&pmid=18945860}}</ref> |
||
It is highly potent agent, capable of damaging cancer cells in very low concentrations, and retains activity in cases where tumor cells are insensitive to paclitaxel.<ref name="pancreas">{{cite journal |author=M. Vulfovich|display-authors=etal|title=Novel advances in pancreatic cancer treatment|journal=Expert Rev Anticancer Ther |volume=8 |issue=6 |pages=993–1002 |year=2008 |doi=10.1586/14737140.8.6.993 |pmid=18533808 |last2=Rocha-Lima |first2=C}}</ref> |
It is highly potent agent, capable of damaging cancer cells in very low concentrations, and retains activity in cases where tumor cells are insensitive to paclitaxel.<ref name="pancreas">{{cite journal |author=M. Vulfovich|display-authors=etal|title=Novel advances in pancreatic cancer treatment|journal=Expert Rev Anticancer Ther |volume=8 |issue=6 |pages=993–1002 |year=2008 |doi=10.1586/14737140.8.6.993 |pmid=18533808 |last2=Rocha-Lima |first2=C}}</ref> |
||